USA flag logo/image

An Official Website of the United States Government

QCM Quantification of Endocrine Disruptor Activity

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
71599
Program Year/Program:
2004 / STTR
Agency Tracking Number:
ES013004
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
OXFORD BIOMEDICAL RESEARCH, INC.
2165 AVON INDUSTRIAL DRIVE ROCHESTER HILLS, MI 48309-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2004
Title: QCM Quantification of Endocrine Disruptor Activity
Agency: HHS
Contract: 1R41ES013004-01A1
Award Amount: $85,395.00
 

Abstract:

DESCRIPTION (provided by applicant): Environmental agents with estrogen-like activity are a major public health issue. Although a variety of assays have been developed to detect binding to the estrogen receptor (ER) and other assays have been developed to monitor subsequent effects on estrogen sensitive gene transcription, an Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) recently reported difficulties with all available methods. We are developing quartz crystal microbalance (QCM) platform technology for the quantitative high-throughput analysis of complex macromolecular interactions. The focus of this project is the development of QCM biosensors for rapid quantification of the influence of endocrine disrupters on the interactions among the estrogen receptor (ER), coactivators or corepressors and the estrogen response element (ERE). QCM has been applied to study interactions of proteins with small molecules, protein-protein interactions, and DMA hybridization. It is expected that QCM will provide heretofore inaccessible quantitative information regarding effects of endocrine disrupters on the kinetics and affinity of the ER for the ERE as well as comparable information about the influence of endocrine disrupters on interactions between the ER and coactivators, corepressors, and other transcription factors whose interactions regulate estrogen-responsive genes in many cell types and organisms. Major advantages of QCM include high sensitivity, low cost, real time label-free, quantitative analysis. Given the U.S. congressional mandate and World Health Organization recommendations for endocrine disrupter testing of chemicals, we anticipate strong market demand for ERE biosensor technology.

Principal Investigator:

Xiangqun Zeng
2483702881
ZENG@OAKLAND.EDU

Business Contact:

Denis Callewaeert
2488528815
CALLEWAE@OXFORDBIOMED.COM
Small Business Information at Submission:

OXFORD BIOMEDICAL RESEARCH, INC.
2165 AVON INDUSTRIAL DRIVE ROCHESTER HILLS, MI 48309

EIN/Tax ID: 382506491
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
OAKLAND UNIVERSITY
544 O'DOWD HALL
OXFORD, MI 48309
RI Type: Nonprofit college or university